Compare KLTR & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | KRRO |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 187.9M |
| IPO Year | 2021 | 2019 |
| Metric | KLTR | KRRO |
|---|---|---|
| Price | $1.60 | $13.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $3.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 1.1M | 85.0K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | $6,392,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.20 | ★ 181.46 |
| 52 Week Low | $1.06 | $5.20 |
| 52 Week High | $2.05 | $55.89 |
| Indicator | KLTR | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 56.58 |
| Support Level | $1.56 | $12.63 |
| Resistance Level | $1.68 | $14.42 |
| Average True Range (ATR) | 0.08 | 0.74 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 38.02 | 52.09 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.